Kura Oncology, Inc.

Kura Oncology filed an officer departure 8-K on June 4, 2026, the only red flag detected in our 90-day monitoring window with no cyber incidents reported. The filing also included related items on officer compensation and financial statements, suggesting potential leadership transition during what may be a critical phase for the biotech's pipeline. A company in clinical-stage oncology faces elevated execution risk when key personnel change, and the timing and context of this departure warrant careful review. The full $49 Report adds leadership impact assessment, 12-month dilution risk score, detailed financing history, and AI-flagged anomalies in compensation and disclosure patterns.